<scp>mTOR</scp> pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta‐analysis

Marques, Ana Elizia Mascarenhas; Elias, Silvia Taveira; Porporatti, André Luís; Castilho, Rogerio M.; Squarize, Cristiane H.; Canto, Graziela De Luca; Guerra, Eliete Neves Silva

doi:10.1111/jop.12390

Cited by 28 publications

(26 citation statements)

References 51 publications

(158 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 The clinical impact of mTOR activation depends on the tumor type, as it has been revealed in 3 recent metaanalyses. [54][55][56] All of them have been established that mTOR activation is associated with worse prognosis in gynecological, gastrointestinal, and head and neck cancers; however, it is not associated with worse prognosis in breast cancer or even associated with good prognosis in some breast cancer types 57 or in lung cancer, 54 and it is inconclusive in prostate cancers.…”

Section: Discussionmentioning

confidence: 99%

Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The pro‐oncogenic nature of the PI3K/mTOR/AKT pathway became evident in various tumors, including HNSCC . The use of rapamycin and rapalogs in cancer treatment began with a focus on identifying biomarkers to predict efficacy of treatment and prognosis of the patient . Clinical trials with rapalogs have been investigated in the treatment of HNSCC .…”

Section: Introductionmentioning

confidence: 99%

“…Clinical trials with rapalogs have been investigated in the treatment of HNSCC . There is evidence suggesting the prognostic association between alteration in this pathway for patients with HNSCC and the resultant poor survival rates . However, no study to date has compared the use of the various agents and efficacy of mTOR inhibition in HNSCC with a focus on survival, the resultant response of the tumor and subsequent toxicity profile to the patient.…”

Section: Introductionmentioning

confidence: 99%

mTOR inhibitor use in head and neck squamous cell carcinoma: A meta‐analysis on survival, tumor response, and toxicity

Patel

Nguyen

Öğretmen

et al. 2020

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) has been rising in incidence primarily related to HPV-associated oropharyngeal cancers. Novel molecular therapeutics are evolving with the mTOR pathway as a new target. Previous studies have shown variable outcomes with relatively low toxicity. This study reports the tumor response, survivability, and toxicity of mTOR inhibitors (mTORi) in HNSCC. Despite expanding research on this pathway, there remains controversy around mTORi use for treatment of HNSCC. Materials and methods: Studies were included if: (a) Used mTORi alone or in combination with other treatment modalities in HNSCC. (b) Site of cancer included were one of the following: nasopharyngeal, oral cavity, oropharynx, hypopharynx or larynx. (c) All stages of cancer and treatment stage (neoadjuvant, adjuvant, and palliative)were included. The rate of adverse events (AEs), tumor response, progression free survival, and overall survival were meta-analyzed.Results: From 1299 publications only 11 studies met inclusion criteria with a combined 232 total patients treated. Two studies used mTORi neoadjuvantly, five adjuvantly, and four in palliative/unresectable/metastatic setting. Monotherapeutic mTORi resulted in stabilization of disease (52.5%), but partial response was the most common response when mTORi were combined with chemotherapy and/or radiation (CRT) (48.1%). Survival rate was the highest in the mTORi combined with CRT.

show abstract

“…Focusing specifically on SCCHN, prior research has found over-expression of mTOR and genomic alteration in the PI3K/AKT signalling pathway to be associated with decreased overall survival rates [10]. In addition, pAKT expression has been proven to be a putative biomarker predictor of response to cetuximab-based chemotherapy [11].…”

Section: Activation Of Pro-survival Pathwaysmentioning

confidence: 99%

Radiotherapy plus EGFR inhibitors: synergistic modalities

Bossi

Platini

2017

Cancers Head Neck

View full text Add to dashboard Cite

Locally advanced (stage III or IV) squamous cell carcinoma of the head and neck (SCCHN) often requires multimodal treatment, consisting of a combination of surgery, radiation, and/or systemic therapy, namely chemotherapy or targeted agents. The expression of the epidermal growth factor receptor (EGFR) has been detected in more than 90% of all cases of SCCHN and has been correlated with decreased survival rates, resistance to radiotherapy, loco-regional treatment failure, and increased rates of distant metastases. This paper discusses several strategies aimed at targeting EGFR in combination with radiation. Until now, cetuximab, an anti-EGFR monoclonal antibody, is the only targeted agent that has been shown to improve overall survival in combination with radiation therapy. However, considering that there are multiple mechanisms of primary and acquired resistance to EGFR inhibitors, we focused on dissecting molecular pathways of EGFR inhibition to find alternative or complementary strategies for increasing tumour responsiveness. We suggest that the combination of treatments targeting the EGFR pathway and drugs aimed at increasing immune responses represent a promising approach that deserves to be further explored.

show abstract

mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta‐analysis

Abstract: This systematic review and meta-analysis support evidence that mTOR pathway proteins can be used as predictive markers for survival in patients with HNC because their expression was significantly associated with poor OS and short DFS.

Cited by 28 publications

References 51 publications

Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma

Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma

mTOR inhibitor use in head and neck squamous cell carcinoma: A meta‐analysis on survival, tumor response, and toxicity

Radiotherapy plus EGFR inhibitors: synergistic modalities

Contact Info

Product

Resources

About